Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
Nicolas
N
Rodondi
Douglas C
DC
Bauer
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D019983:Guideline Adherence / Q000592:standards*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000592:standards*; D018570:Risk Assessment; D014481:United States / Q000453:epidemiology
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin